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Abstract
An important checkpoint in the progression of melanoma is the metastasis to lymph nodes. Here, 
to investigate the role of lymph node NK cells in disease progression, we analyze frequency, 
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phenotype and functions of NK cells from tumor-infiltrated (TILN) and tumor-free ipsilateral 
lymph nodes (TFLN) of the same patients. We show an expansion of 
CD56dimCD57dimCD69+CCR7+KIR+ NK cells in TILN. TILN NK cells display robust cytotoxic 
activity against autologous melanoma cells. In the blood of metastatic melanoma patients the 
frequency of NK cells expressing the receptors for CXCL8 receptor is increased compared to 
healthy subjects, and blood NK cells also express the receptors for CCL2 and IL6. These factors 
are produced in high amount in TILN and in vitro switch the phenotype of blood NK cells from 
healthy donors to the phenotype associated with TILN. Our data suggest that the 
microenvironment of TILN generates and/or recruits a particularly effective NK cell subset.
Introduction
T cell mediated immune responses to melanoma antigens have been documented 
extensively1,2. NK cells contribute to anti-tumor immunity, which is traditionally analyzed 
using human peripheral blood NK cells3. In contrast, the role of NK cells in the progression 
of melanoma to lymph node metastasis has not been investigated. We therefore set out to 
analyze and compare NK cell phenotype and responses in tumor infiltrated lymph nodes 
(TILN), ipsilateral tumor-free lymph nodes (TFLN) and peripheral blood (PBL) in a cohort 
of stage III-IV melanoma patients. The NK cells in healthy lymph nodes are predominantly 
CD56bright 1. The comparative analysis of the lymphocyte subsets from lymph nodes and 
autologous peripheral blood reveals a perturbation of NK cell subpopulation frequencies in 
the TILN where the CD56dim CD3− NK cells prevail. The phenotype of the NK cells 
present in the tumour infiltrated lymph nodes resemble a recently described mature and 
highly cytotoxic NK subset4,5. The TILN associated NK subset is functionally active and 
mediates a robust anti-melanoma cytotoxicity. Moreover, CXCL8, CCL2 and IL6 dominate 
the lymph node-tumor environment and patient’s peripheral blood NK cells indeed express 
higher amount of CXCR2 and CCR2. Our study reveals an unexpected cross talk between 
the tumor niche environment and NK cells and identify a selective anti melanoma response 
mediated by CD56dimCD57+CD69+CCR7+KIR+ NK subset.
Results
Frequency and phenotype of NK cells in melanoma patients
We found roughly two-fold more NK cells within TILN (1.3±0.9% of the total lymphocyte 
population, n=31) versus TFLN (0.7±0.3%, n=12, P=0.02). We analyzed NK cell subsets in 
blood and lymph nodes by flow cytometry, using the gating strategy depicted in 
supplementary figure 1. NK cells can be broadly divided in CD56dim cytotoxic cells, which 
represent the majority of NK cells in the blood, and in CD56bright cytokine producers, which 
are the most frequent NK cells in lymph nodes 1. Interestingly, we found that pattern of 
distribution of these two subsets was significantly perturbed in the blood as well as in the 
infiltrated lymph nodes of melanoma patients (Fig. 1a,b). The mean frequency of NK cells 
in patients’ peripheral blood (P-PBL) was 5.4±2.0% (n=10) with a prevalence of the 
CD56dim subset (56.5%±17.5) over the CD56bright subset (43.5±17.5%) (Fig. 1b); the latter 
ratio was significantly different from that we and others have found in healthy individuals’ 
PBL6 (Fig. 1b; H-PBL, CD56dim=87.8±6.3%; CD56bright=12.2±6.3%, n=3, P<0.001). As to 
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the lymph nodes, the pattern was now reversed (Fig. 1b); the CD56dim subset prevails in the 
TILN of all the patients tested (CD56dim=55.5±21.5%, n=31, CD56bright=44.5±21.5%, 
P<0.05) whereas the CD56bright subset prevailed in TFLN (CD56dim=31.7±10.8%, n=31, 
CD56bright=68.3±10.8%, n=12, P<0.001) just as they do in lymph nodes of healthy 
individuals. Thus, NK cell subsets were abnormally distributed in melanoma patients, with 
the potentially cytotoxic CD56dim NK cells being underrepresented in patients PBL and 
overrepresented in TILN.
The activation marker CD69 in TILN NK cells was even higher than in peripheral NK cells 
from both patients and healthy donors (Fig. 1 c, P ≤ 0.005).
Maturation and activation markers were measured by multiparametric flow cytometric 
analysis in TILN, TFLN and PBL. Both CD56dim and CD56bright NK cell subsets within 
TILN showed higher expression of CD57, CD69 and CCR7 whereas CD16 expression was 
significantly augmented in TILN only in the CD56bright subset (Fig. 1d). The CD57 marker 
has been recently associated with a late, possibly final stage of NK cell maturation5. CD57+ 
NK cells were 3.4 fold more abundant in TILN (48±17.6%, n=31) than in TFLN (14±4.2%, 
n=12) (P=0.002). It should be noted that the intensity of CD57 staining of NK cells in TILN 
was weaker compared to the CD57+ subpopulation in the blood (Fig. 1a). Inhibitory Killer-
cell Immunoglobulin-like Receptors (KIRs) control several functions of mature NK cells7, 8. 
In spite of the marked variability in KIR expression by TILN and TFLN NK cell subsets the 
expression of the two inhibitory KIRs stained by the CD158b-specific mAb KIR2DL2 and 
KIRDL3 was higher on TILN NK cells than on TFLN NK cells (n=3, P=0.002) (Fig. 1d). In 
line with these data, the intensity of the staining of TILN NK cells by mAbs that recognize 
KIR3DL2, KIR2DL1/S1, KIR2DL2/L3/S2, KIR2DL1/S1 and CD94 was higher than that of 
TFLN NK cells in three representative patients (AMM16, 17 and 18, Supplementary Fig. 
2a); the difference was statistically significant (P<0.005, for KIR2D, 2DS, 3DL and 
KIR2DL1/S1; P<0.05 for CD94) (Supplementary Fig. 2a and b). There was also a trend 
towards a higher expression of activating receptors NKG2D, DNAM-1 and Natural 
Cytotoxicity Receptors (NCR, also known as NKP30, NKP44 and NKP46) on TILN NK 
cells in seven metastatic melanoma patients (AMM5, 6, 11, 12, 13, 15 and 16). We have 
previously reported that NCRs and DNAM-1 are key receptors for NK cell recognition of 
melanoma cells and, in particular, of melanoma cell lines derived from lymph node 
metastases; the latter are more susceptible to NK cell recognition because they express 
higher levels of ligands for NCRs9. Together these results argue in favour of the possibility 
that TILN is the site where NK cells preferentially enrich and express receptors (KIR, NCR) 
and markers of maturation (CD57, CD56dim) and activation (CD69) suggestive of a more 
differentiated effector cell phenotype. Moreover these CD56dim NK cells expressed the 
lymph node homing chemokine receptor CCR7 (Fig. 1d), suggesting that NK cells actively 
migrate into the TILN from non-lymphoid tissues and from the circulation. The pattern we 
observed can be due to migration of already fully mature CD57+ NK cells to the TILN, or to 
maturation in situ of immature NK cells migrated from the periphery to TILN. The reduced 
proportion of CD56dim cells in the PBL of melanoma patients argues in favor of the former 
possibility. On the other hand, the low CD57 staining on NK cells in TILN suggests that this 
subpopulation does not correspond exactly to the CD57 bright NK cells in the blood. In 
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either scenario, our data suggest that TILN might be an important site for NK cell-mediated 
immunosurveillance against melanoma metastases.
Analysis of cytokine milieu in TILN and TFLN
To test whether the phenotypical differences between the NK cells resident in TILN and 
those resident in TFLN were due to different cytokine milieus, we performed transwell co-
culture experiments. We observed a strong increment in the percentage of both CD69 and 
CCR7 expressing cells from TFLN treated with TILN supernatants, reaching very similar 
levels to TILN NK cells (Fig. 2a); this suggests that TILN supernatants contain soluble 
factors able to convert the phenotype of TFLN NK cells into a phenotype similar to that of 
TILN NK cells. Thus, we quantified selected cytokines and growth factors in culture 
supernatants of lymph node-derived cell suspensions from 0 to 96 hrs. TILN produced more 
CXCL8 (Fig. 2b) (P<0.005, n=3), IL-6, and CCL2 than TFLN (Fig. 2c) (P<0.05, n=3). 
Taken together these results show that TILN have a different cytokine milieu which may 
account for the peculiar NK cell phenotype observed. The expression of CXCL8 and CCL2 
chemokines in TILN suspensions might be an early consequence of target cell recognition 
by NK cells, which has a low threshold for activation10. The production of inflammatory 
cytokines TNFα and IFN-γ by NK cells, instead, requires stronger activation, which may not 
be attained in the TILN microenvironment, where tumor and NK cells are exposed to other 
cytokines and tumor growth factors that may be suppressive. Notably, the autologous 
melanoma metastasis itself produced detectable amounts of CXCL8, IL-6 and CCL2. To 
assess the impact of these soluble factors on NK cells phenotype, we treated healthy donors 
PBL cells with single cytokines or a combination of them (Supplementary Fig. 3). 
CD56bright was the only cell subset responsive to the combination of all three cytokines 
since it showed an upregulated expression of CD69, CD57, CD16, CD158 and CCR7 (Fig. 
2d). Similar data were obtained using purified NK cells.
The expression of the receptors for CXCL8, CCL2 and IL-6 was compared in healthy 
donors and melanoma patient’s peripheral blood NK cells. The frequency of CXCR2 was 
significantly higher in the CD56dim compartment in patients’ peripheral blood with respect 
to healthy donors. There was a trend towards higher expression of both CXCR2 and CCR2 
in the CD56bright subset in patients’ PBL. Noteworthy, no differences were found in T cells 
compartment between healthy donors and patients. The frequencies of CXCR2 and CCR2 
expressing NK cells were higher than T cells with these receptors in patient’s peripheral 
blood. However, only the CD56dim CXCR2 expressing subset and CCR2 CD56bright reached 
the statistical significance (Fig. 2e).
Therefore, it is conceivable to propose that the presence of metastatic cells lead to a cytokine 
environment in the patients’ lymph node that is dominated by CXCL8, CCL2 and IL-6 (Fig. 
2b). These soluble factors may induce in situ maturation of CD56bright CD3− NK cells to 
become more mature and cytotoxic CD57+KIR+CD69+CCR7+ NK cells (Fig. 2d). 
Moreover, CXCL8 and CCL2 produced by metastatic lymph nodes may recruit CXCR2+/
CCR2+ cells among both subsets of circulating CD56bright and CD56dim NK cells (Fig. 2e).
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NK cells cytotoxicity from tumor-infiltrated lymph nodes
To directly quantify the anti-tumor activity of patients’ NK cell subsets, we measured NK 
cell cytotoxicity against patients’ autologous melanoma cells after short-term cultures. We 
included NK cells isolated from patients’ TILN, TFLN and PBL, as well as NK cells 
isolated from healthy donor PBL. TILN NK cells showed the highest and TFLN NK cells 
the lowest cytotoxic activity (Fig. 3a and 3b). Altogether, these data demonstrate that 
autologous TILN-derived NK cells kill lymph node metastatic melanoma cells more 
efficiently than autologous TFLN- and PBL-derived NK cells (P<0.005, n=6), or allogeneic 
PBL-derived NK cells from healthy donors (P<0.005, n=4).To confirm the cytotoxic 
potential of NK cells in vitro, we used a degranulation assay based on the expression of 
CD107a. We measured basal CD107a surface expression directly after explanting TILN and 
TFLN of five melanoma patients (AMM17, 18, 19, 20, 21). In all the patients tested, the 
expression of CD107a was higher on NK cells from TILN, particularly within the CD56dim 
cells (P=0.012) and the CD57+ NK cells (P=0.005) (Fig. 3c). We also measured 
degranulation in response to K562 erytroleukemia cells, the gold standard target for NK 
cells. Interestingly, only TILN NK cells were clearly activated to degranulate by K562 
pulsing, while the TFLN NK cells were unresponsive (Fig. 3d). To assess whether these 
highly cytotoxic TILN CD57+CD56+ NK cells maintain proliferative potential, we 
measured the expression of Ki67, a marker of cycling cells. CD57+CD56+ NK cells 
contained 6 fold more Ki67+ cycling cells (60.1%±13.4) than CD57-CD56+ NK cells 
(10.4% ±10.2), thus they can proliferate (Fig. 3e).
Frequency of CD57+CD56dim NK cells in TILN and prognosis
The peculiar phenotype of TILN NK cells and their surprisingly high cytotoxic activity 
against autologous melanoma cells, prompted us to investigate whether the presence of the 
CD57+CD56dim subset in TILN would correlate with clinical outcome. The ratios between 
CD57+CD56dim and CD57+CD56bright cells, normalized on the total NK cells percentage in 
TILN, showed considerable variability among the 20 melanoma patients’ TILN investigated, 
distributing over a range between 1.0 and 16.9 (Fig. 4a). We thus divided the patients into 
two groups, one with a ≥6 ratio and the other one with a <6 ratio. Since patients with higher 
ratio mainly belong to stage III, we stratified the patients according to disease stage (Fig. 
4b), and found a trend towards association between overall survival and NK ratio within 
stage III patients.
Although suggestive of a potential role for lymph node NK cells in clinical outcome, this 
association must be considered as a preliminary observation, to be tested in a much larger 
cohort in order to assess whether it is an independent variable. In contrast, there was no such 
pattern when patients were grouped according to the frequencies of CD57+CD8+CD3+ 
cytotoxic T cells (Supplementary Fig. 5) or Foxp3+CD25+CD3+ T regulatory cells 
(Supplementary Fig. 6). The differences in survival cannot be explained by novel therapies 
for metastatic melanoma such as BRAF inhibitors and anti-CTL4-A or PD1 monoclonal 
antibodies, since the patients studied here were diagnosed before the introduction of these 
treatment protocols. We noted that male patients dominated in the group with <6 ratio (10 
males vs 2 females) but not in the group with >6 ratio (3 males vs 3 females), and males 
have been reported to have a worse prognosis in metastatic melanoma11. We therefore 
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cannot exclude gender as a contributing factor in the clinical outcome (Supplementary Table 
1).
Discussion
Experimental evidence supports the notion that peripheral blood CD56bright NK cells give 
rise to CD56dim NK cells which can be further subdivided into subsets on the basis of 
surface markers and function. CD57 expression is acquired at later stages and marks 
terminally differentiated cells with high cytolytic activity but very low proliferative 
potential5, 6,12. Under physiological conditions the NK cell population in lymph nodes is 
dominated by CD56bright cells. We found a striking reversed pattern in tumor infiltrated 
lymph nodes where most NK cells are CD56dim CD57+. These cells express activation 
markers and are highly cytotoxic against autologous melanoma cell lines. In view of these 
findings the ratio between the CD57+CD56dim and the CD57+CD56bright, normalized on the 
total NK cell percentage in TILN, could represent a valid index of terminal differentiation 
toward fully competent and highly cytotoxic NK cells. It is remarkable that despite the 
presence of Treg cells (Supplementary Fig. 4), these KIR+CD57+ NK cells are activated, as 
demonstrated by the expression of CD69 and their ability to readily degranulate. The high 
functional activation status of TILN NK cells can even be further increased by ex vivo 
exposure to tumor cells such as K562 cells, despite the possible tolerogenic environment. 
However, it should be noted that the TILN milieu is characterized by considerable IL-6 
production (Fig. 2b), known to drive CD4 T-cell differentiation away from Treg function 
even in the presence of TGF-β13. Noteworthy, melanoma metastases produce CXCL8 14 and 
the senescent melanoma cells secrete IL-6, CCL2 and CXCL8 15. The serum concentration 
of CXCL8 increases during melanoma progression16. Thus, NK cells may be specifically 
recruited from the blood to the melanoma infiltrated lymph nodes using the combination of 
receptors that facilitate homing (CCR7 and CXCR2) and tumor targeting (CXCR2 and 
CCR2).
The described results suggest that the ratio between CD56dim CD57+and 
CD57+CD56bright cells in TILN is biologically important and this preliminary observation 
should be further explored as a prognostic marker in metastatic melanoma. One possible 
mechanistic/causal scenario that emerges from this observation is that during the progression 
of malignant melanoma to lymph nodes’ metastasis, CD56dim/CD57+ NK cells become 
enriched in infiltrated lymph nodes, either by selective recruitment or by expansion (or a 
combination of the two). These NK cells then act to limit further spread. It is however also 
possible that the differential reactivity patterns in the TILN represent consequence rather 
than cause of differential tumor progression. For example, association with prognosis might 
be explained by the ability of particularly aggressive tumors to prevent the enrichment of the 
fully differentiated NK cell subset. These and other aspects of lymph node NK cell reactivity 
would be interesting to analyze further in a larger cohort of patients.
To our knowledge this is the first report demonstrating that CD56dim CD57+NK cells can be 
found in lymph nodes. It will be interesting to investigate how this subpopulation relates to 
‘memory’ NK cells that expand after CMV infection in mice and humans17, 18. Besides 
shedding light on the role of NK cells in tumor protection, our data suggest that TILN NK 
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cells should be considered as interesting candidate for the design of new adoptive 
immunotherapy protocols. Lymph nodes explanted during common clinical practice may be 
a good source of proliferating and highly cytotoxic NK cells that can be expanded ex vivo 
and subsequently administered to patients.
Materials and Methods
Isolation of lymphocytes and melanoma cell cultures
Lymphocytes and melanoma cells were isolated from surgically removed tumor-invaded 
lymph nodes (TILN) and ipsilateral tumor-free lymph nodes (TFLN) of AJCC stage IIIc or 
IV melanoma patients. Patients were admitted to Fondazione IRCCS Istituto Nazionale dei 
Tumori, Milan, Italy. Patients had no history of previous chemotherapy or immunotherapy. 
All the lesions were histologically confirmed to be cutaneous malignant melanomas. Written 
informed consent was obtained from all patients in accordance with the Declaration of 
Helsinki to the use of human biological samples for research purposes. Lymphocytes from 
TILN of 38 patients (named with the acronym AMM and numbered from 1 to 56), TFLN, 
and melanoma cells from TILN, were isolated by mechanical disaggregation of surgical 
specimens. Briefly, tumor specimens were placed in RPMI 1640 (Lonza Verviers, Belgium) 
supplemented with antibiotics penicillin and streptomycin (Lonza) and minced into 1-2 mm3 
fragments by surgical scalpels. Further tissue disaggregation was achieved by forcing 
fragments through a metallic mesh with the aid of a sterile siringe plunger. After 
centrifugation the cell suspension was treated with trypsin (Lonza) and DNAase (Sigma) for 
2 min at room temperature to remove dead cells. After two washes and centrifugation, 
different aliquots of the cell suspensions were used for cryopreservation, for deriving tumor 
cell cultures and for isolation of lymphocytes. Melanoma cell lines were established by 
culture of cell suspensions in 25 cm2 tissue flasks in RPMI 1640 supplemented with 2% 
glutamine (200mM, Invitrogen), penicillin (100 U/ml), and streptomycin (100 μg/ml) and 
10% heat-inactivated fetal calf serum (FCS, Biological Industries), at 37°C in humidified 
CO2 atmosphere. Melanoma cell lines were routinely tested for the absence of Mycoplasma 
contamination by a PCR-based kit (PromoCell). SP11-763.7419 and SP11-TP61.520 mAbs 
that recognize specific melanoma markers were used to validate histologically primary 
melanoma cell lines derived from individual patients. The human melanoma metastatic cell 
lines were grown for not more than 9-10 in vitro passages. Lymphocytes from TILN-derived 
cell suspensions were isolated by Ficoll-Paque (Biopaque) gradient separation.
Isolation of NK cells from short-term TILN and TFLN cultures
NK cells were purified from TILN and TFLN cell suspensions in selected experiments, 
using the NK cell Isolation kit negative selection and VarioMACS (Miltenyi Biotec) 
according to the manufacturer’s instructions for the depletion of non-NK cells. Briefly, after 
thawing, TILN and TFLN cell suspensions in RPMI 1640 medium were cultured overnight 
at 37°C in a 5% CO2 humidified atmosphere. After a preliminary passage through a Ficoll 
column (Biopaque) to remove debris and dead cells, the purity of NK cell preparations, 
determined by cytofluorometric analysis, was above 95%. Freshly enriched NK cells were 
suspended in IMDM culture medium (Life Technology) supplemented with Penicillin (100 
IU/ml) and Streptomycin (100 μg/ml), 10% FBS (Invitrogen). Peripheral blood lymphocytes 
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(PBL) were isolated from blood of patients with melanoma or of healthy donors by density 
gradient centrifugation over Ficoll-Paque (Biopaque).
Antibodies
Q66 (KIR3DL2)/IgM (at 1:5 dilution), Z27 (KIR3DL1/S1)/IGg1 (at 1:10 dilution), GL183 
(KIR2D2/3/S2)/IgG1 (at 1:20 dilution), XA185 (CD94)/IgG1 (at 1:20 dilution), Z 270 
(NKG2A) IgG1(at 1:5 dilution) supernatants produced in our laboratory (A.M.). FITC-
antiCD57/IgM (322306 at a 1:100 dilution), PE-antiCD57/IgM (322312 at a 1:100 dilution), 
PerCP/Cy5.5-CD3/IgG1 (344807 at a 1:100 dilution) PE-antiKi67/IgG1 (350503 at a 1:50 
dilution), PE/Cy5 anti-human CD56/IgG2a (304608 at a 1:100 dilution), APC-antiCD3/
IgG2a (317317 at a 1:100 dilution), PE-antiFoxp3 /IgG1(320007 at a 1:100 dilution), PE-
antiNKp44/IgG1 (325108 at a 1:100 dilution), PE-antiNKp30 IgG1 (325208 at a 1:100 
dilution), PE-antiNKp46 IgG1 (331908 at a 1:100 dilution), PE-antiDNAM1/IgG1(338305 
at a 1:100 dilution) and PE-antiNKG2D/IgG1(320806 at a 1:200 dilution), PE-antiCCR7/
IgG2a (353204 at a 1:100 dilution), PE-antiCD16/IgG1 (302008 at a 1:300 dilution), FITC-
antiCD69/IgG1 (310904 at a 1:100 dilution) were from BioLegend. FITC-antiCD3/IgG1 
(11-0036 at a 1:100 dilution) and APC-antiCD3/IgG1 (11-0036-42 at a 1:100 dilution) were 
from eBioscience. PE-Cy7-antiCD56/IgG1 (560916 at a 1:100 dilution), PE-CD69/IgG1 
(341652 1:50 dilution) and FITC-CD158b/IgG2b (559784 at 1:50 dilution) were from BD 
Pharmingen For the cytokines receptors staining on patients and healthy donor lymphocytes, 
the followed antibodies were used: APC-antiCD126 (IL-6R)/IgG1 (cod.562090 at 1:50 
dilution), APC-antiCD182 (CXCR2)/IgG1 (cod.551127 at 1:10 dilution), APC-antiCD192 
(CCR2)/IgG2b (cod.558406 at 1:10 dilution) from Miltenyi Biotec, and 7AAD Staining 
Solution for the cell viability from BD Pharmingen.
Flow-cytometry analysis
Briefly 2 × 105 cells from the total LN suspension were stained with the indicated antibodies 
followed by flow cytometric analysis. In the indirect staining method the cells were firstly 
incubated with an appropriate primary mAb followed by FITC (Sigma) conjugated goat 
anti-mouse secondary antibody. In all experiments the isotype-matched controls were used 
to set up the negative values. Cells were fixed in 1% formaldehyde for data analysis. Sample 
fluorescence was measured by the Fluorescence-Activated Cell Sorter FACSCalibur 
apparatus (Becton Dickinson) and data were analyzed by using the Cell-Quest software 
(Becton Dickinson).
For intracellular staining to investigate the percentage of Treg cell, cell pellets were 
resuspended in PBS with 2% FBS and stained with fluorochrome-conjugated anti-CD4, then 
fixed with 3% formaldehyde (Sigma) in PBS, permeabilized with PBS with 2% FBS and 
0.5% saponin (Sigma), and stained with PE-antiFoxp3 /IgG1.
For Ki67 staining, BD Cytofix/Cytoperm kit was used, according to manufacturer’s 
instructions. Briefly cell pellets were resuspended in PBS with 2% FBS and surface stained 
with fluorochrome-conjugated anti-CD56, anti-CD57 and anti-CD3, then fixed, 
permeabilized, and intracellularly stained with PE-Ki67/IgG1.
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In the direct staining for the cytokines receptors, cells were firstly incubate with Human 
serum for 15 minutes and then acquired by a FACS Canto II apparatus (Becton Dickinson). 
The data were analyzed by Flow-Jo version 7.6.4 software analysis.
Microarray cytokine assay
For cytokine profile analysis, TILN, TFLN and tumor samples of AMM 8,9,16 metastatic 
melanoma patients were thawed and cultured with complete RPMI 1640 medium. Then 
1000 μl of culture supernatant were removed at 0, 12, 24, 48, 96 hrs time points and 
analyzed by biochip array analyzer with the RANDOX cytokine & growth factors array 
(CTK) micro array kit, for the simultaneous quantification of interleukin-2 (IL-2), IL-4, 
IL-6, CXCL8, IL-10, Vascular Endothelial Growth Factor (VEGF), Interferon Gamma 
(IFN-γ), tumour necrosis factor alfa (TNFα), IL-1α, IL-1β, Monocyte Chemoattractant 
Protein-1 (MCP/1) and Epidermal Growth Factor (EGF). This assay was performed 
following the manufacturer’s recommended procedure. Beads were read on the Bio-Plex 
suspension array system. Data were analyzed using Bio-Plex manager software with 5PL 
curve fitting. The limit of detection for this assay is ≈10 pg/ml (based on detectable signal 
±2 SD above background). TGF-β production was evaluated by a specific ELISA kit 
following manufacturer’s instructions (R&D Systems and Biosource International).
Cytotoxicity assay
Purified NK cells from TILN, TFLN, and PBL of melanoma patients or healthy donors were 
cultured 48hrs in presence of 200 IU of IL2 (Chiron) than used as effectors against related 
metastatic melanoma in vitro established tumour cells using the fluorescent carboxy-
Fluorescein Diacetate c’FDA NK assay. Briefly, the target cells were labeled with c’FDA 
(Molecular Probes). Target cells were mixed with effector cells at different E: T ratios for 3 
hours in 200 μl of RPMI 1640 medium at 37° C in a humidified 5% CO2 incubation. The 
specific lysis of target cells was calculated as follows: % specific lysis = (CT- TE /CT) ×100 
(where CT= mean number of fluorescent target cells in control tubes and TE= mean number 
of fluorescent cells in target + effectors tubes).
CD107a mobilization assay after K562 pulsing
Freshly enriched lymphocytes from TILN and TFLN cell suspension of metastatic 
melanoma patients were cultured at 37°C in 5% CO2 to different (4:1, 10:1, and 20:1) 
effector: target ratio with K562 (ATCC) in the presence of PE-conjugated CD107a/IgG1 
antibody (BD Pharmingen) in U bottom 96 well plates. After 1 h, Brefeldin A (5μg/ml, 
Sigma) was added to cultures for an additional 3 h of incubation. At this time cells were 
collected, washed with PBS with 2% fetal bovine serum (FBS) stained with anti-CD56 PE-
Cy5 (Beckman-Coulter-Immunotech), anti-CD3 FITC (Beckman-Coulter-Immunotech) or 
alternatively with anti-CD3 APC (BD Pharmingen) and analyzed by flow cytometry.
Statistical analysis
Statistical computations were done using the GraphPad Prism 5.0 software for Windows. 
Data obtained from multiple experiments are calculated as mean ± SD and analyzed for 
statistical significance using the 2-tailed Student t-test, for independent groups, or ANOVA 
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followed by Bonferroni correction for multiple comparisons. P-values less than 0.05 were 
considered statistically significant. We analyzed survival time after surgery in 20 cancer 
patients. We considered tumor stage (III and IV) and the CD57+CD56dim/
CD57+CD56bright ratio (ratio < 6 and ratio ≥ 6) as potential predictors. The value 6 of the 
ratio was chosen because it was the best discriminatory cut off value for survival. We 
obtained survival curves with the Kaplan-Meier product-limit estimator. We tested for 
differences between groups with the log-rank test. We tested for trend in survival across 
groups with Cox regression including the groups a numeric covariate. We verified 
proportionality of the hazards with Schoenfeld’s residuals. We tested the association 
between stage and ratio with the Fisher’s exact test. The analyses were performed with Stata 
version 13 (Statacorp, College Station, TX, USA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Frequency and phenotype of human NK cells in melanoma patients
(a) Representative example (left) for cytofluorimetric analysis of CD56+CD3− NK cell 
subsets distribution from TILN, TFLN and PBL (P-PBL) in a metastastic melanoma patient 
in comparison with healthy donor PBL (H-PBL), in the same experimental conditions. Two 
regions were selected to represent respectively CD56bright and CD56dim populations. Bar 
graph (right) report mean±SD of the frequency of CD56dim and CD56bright NK subsets 
within TILN (black column, n=31) and TFLN (white column, n=12) gated on lymphocytes 
of all metastatic melanoma patients tested. In parallel light grey columns show the frequency 
of CD56dim and CD56bright NK subsets within peripheral blood lymphocytes of patients (P-
PBL, n=10) and dark grey columns that of healthy controls (H-PBL, n=3). (b) Expression of 
CD57, CD16 and CD158b on CD56dim and CD56bright NK cell subsets from TILN, TFLN 
and P-PBL. Dot plots from one representative patient are presented. The quadrant marker 
has been set according to the isotype controls; to corroborate the validity of the markers T 
cells where used as internal negative control in vertical and the bright/dim boundary in 
horizontal. The identical quadrant marker has been applied on all the plots. (c) Expression of 
CD57, CD16, CD158b, CCR7, CD69 on CD56dim and CD56bright NK cell subsets. Bar 
graphs report mean±SD of the percentage of positive cells for each indicated marker in 
gated NK cells from TILN and TFLN of metastatic melanoma patients (n=12). (d) CD69+ 
CD56+CD3− NK cell subsets frequencies from TILN (n=31), TFLN (n=12), P-PBL (n=10) 
and H-PBL (n=3). Values shown are the mean±SD of percentages of double positive cells 
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indicated. In all experiments shown P value is calculated by ANOVA followed by post-hoc 
Bonferroni test.
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Figure 2. Analysis of cytokine milieau in melanoma infiltrated and tumor free lymph nodes
(a) Transmissible factors’ influence on CD56 cell subset frequency and CD69 and CCR7 
cell surface expression was evaluated in transwell cocultures. TILN and TFLN samples 
(n=3) were analysed for CD69 and CCR7 expression within CD56dim and CD56bright NK 
cell subsets. Each specific bar pattern represents the transwell condition with TFLN, TILN 
or PBL in the upper chamber of the transwell and TFLN or TILN in the lower one. The bar 
diagram shows the mean of values ± SD (ANOVA, n=3). (b, c) Cytokine production in 
supernatant of TILN, TFLN and melanoma tumor samples. The histogram reports CXCL8 
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production by tumor cells (grey column), TILN lymphocytes (black column) and TFLN 
lymphocytes (white column) as mean±SD of three independent experiments (b). IL-6, 
CCL2, VEGF release by tumor cells, TILN and TFLN lymphocytes (the results represent 
mean±SD of three separate experiments, ANOVA) (c). (d) The combination of IL6, CXCL8 
and CCL2 can influence CD56bright phenotype on CD56+CD3− NK cells derived from 
peripheral blood of healthy donors. Bars shows the percentage ± SD of CD56dim (left panel) 
and CD56bright (right panel) expressing each indicated marker. Results shown are 
representative of three independent experiments. Statistical analysis is indicated (ANOVA). 
(e) Frequency of NK and T cell subsets (CD56bright+CD3−; CD56dim+CD3−; CD56-CD3+) 
expressing the CXCL8 receptor (CXCR2), CCL2 receptor (CCR2) and IL6 receptors in 
healthy donors (n=8) and melanoma patients peripheral blood (n=9). Each dot represents a 
different patient or healthy donor. Bars represent mean values. Statistical analysis is 
indicated (ANOVA).
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Figure 3. NK cells from tumor-infiltrated lymph nodes have strong cytotoxic potential
(a, b) Cytotoxicity of NK cells against autologous melanoma cell lines. The graph reports 
the mean percentage specific lysis ±SD of at least 3 individual representative experiments 
performed at the indicated Effector:Target (E:T) ratios. The figure compares killing by 
autologous NK cells isolated from patients’ TILN (circle symbol) and TFLN (black square) 
or allogenic NK cells isolated from healthy donors’ PBL (H-PBL, black triangle) (a). 
Comparison between cytotoxicity of autologous NK cells isolated from TILN (circle 
symbol, n=6), patients’ PBL (P-PBL, black triangle, n=4) and allogenic NK cells isolated 
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from healthy donors’ PBL (H-PBL, white triangle, n=4) (b). Statistical analysis is indicated 
(ANOVA). (c) Basal CD107a surface expression on TILN- and TFLN-NK cells from 2 
representative (AMM18 and AMM21) patients, as assessed by FACS analysis. Numbers in 
dot plots indicate the percentage of CD107a positive cells within CD56dim and CD56bright 
NK subsets (upper panels) or alternatively within CD57+CD56+ NK cells (lower panels). 
The dot plot quadrants are set according to the isotype IgG control for TILN and TFLN as 
shown in the figure. In the CD56 dot plots two additional regions identify bright and dim 
NK cell subsets. The bar diagrams (right) refer to the mean of values ± SD of experiments 
performed in 5 metastatic melanoma patients (ANOVA). (d) Two representative metastatic 
melanoma patients (AMM17 on the left and AMM20 on the right) FACS analysis of the 
CD107a mobilization assay gating on CD56+CD3− TILN and TFLN NK cells after K562 
pulsing at different E:T ratios. Quadrants are drawn according to the IgG isotype control for 
TILN and TFLN, as shown. The bar diagram (right) shows the mean of values ± SD (n=4) 
expressed as fold increase of CD107a expression in target pulsed NK cells over NK cells 
alone. (e) Ki67 intracellular staining TILN CD57+CD56+ NK. The bar diagram (right) 
shows the mean of values ± SD (n=5).
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Figure 4. Stratifying by stages patient’s survival in groups with high or low frequency of 
CD57+CD56dim NK cells in tumor-infiltrated lymph nodes
(a) CD57+CD56dim/CD57+CD56bright ratio was calculated as a proportion of total NK cell 
frequency in the melanoma infiltrated lymph nodes (TILN) of each metastastic melanoma 
patient. (b) Kaplan-Meier survival curves in 7 patients with CD57+CD56dim/
CD57+CD56bright ratio≥6 (continuous line), 6 patients with CD57+CD56dim/
CD57+CD56bright ratio<6 stage III (dashed line) and with 6 patients CD57+CD56dim/
CD57+CD56bright ratio<6 in stage IV (dotted line). The curves were compared with Log 
Rank Test (P=0.004) and a test for trend (P=0.00068).
Ali et al. Page 18
Nat Commun. Author manuscript; available in PMC 2015 June 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
